Live Terminal | Security Analysis of UTHR
TERMINAL beta
Version: 0.1
Timestamp: 1709193022.750663
Options
0Q3.F
53.76%
006220.KS
49.51%
B7J.DE
48.43%
000540.KS
48.07%
BBAI-WT
47.26%
HANA.L
-44.06%
PHLL.L
-50.14%
RAL.PA
-52.20%
GOLL4.SA
-52.40%
HGEN.L
-54.91%
AAPL $180.88 -0.96%
AMD $176.37 -0.92%
AMZN $173.96 0.24%
BRK-B $413.02 1.01%
GOOG $137.26 -2.03%
IBM $184.92 0.03%
INTC $42.16 -1.35%
JNJ $161.21 0.14%
JPM $184.74 0.70%
META $487.18 0.03%
MSFT $407.70 0.05%
O $52.16 -0.28%
TSLA $203.55 1.91%
WMT $59.72 0.21%
QQQ $435.27 -0.5325%
TLT $93.52 0.6349%
VUSA.DE $88.94 0.3317%
VUAA.DE $88.27 0.2863%
FJPR.L $5.63 -0.5650%
VWRP.L $97.51 -0.0102%
VWRL.L $98.20 0.0255%
EMGU.L $3.55 -1.1847%
RDVY $52.62 -0.1518%
FLOT $51.04 0.0294%
SCHZ $45.68 0.2414%
IBB $139.42 -1.0434%
C020.DE $21.34 0.0000%
DFAX $24.53 -0.6480%
LYP6.DE $224.95 -0.3985%
MEUD.PA $225.01 -0.2880%
IQQW.DE $65.41 0.0643%
IDWR.L $70.89 -0.0775%
EXS1.DE $147.20 0.2452%
XESC.L $6900.00 0.0290%
DFAU $35.18 -0.2269%
ACWV $103.29 -0.3377%
VHYD.L $63.68 -0.2897%
VGWD.DE $58.77 -0.1699%
FXKZ.ME $303.00 0.0000%

Latest articles

No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.

Sentiment statistics ?
UTHR
μ null
null
null

Financial Histories

Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.

Overview
UTHR
Latest Performance
UTHR$226.04
$-0.71 • -0.31%
UTHR
Price 226.04
Change Pct -0.31
Change Abs -0.71
Market Cap 10.6 billion
Eps 19.80
Pe Ratio 11.42
Outstanding Shares 47.1 million
Volume 135824
Avg Volume 365462
Industry Biotechnology
Sector Name Health Care
Country Short Name US
Announcement Earnings 2024-05-01 00:00:00+00:00
All metrics in USD or %.
Dividends

There is no dividend data to display. Refer our Dividend calendar for other accurate data.

Risk Profiles

Please sign up and become a member to view all risk profiles.

Focus

The 'Focus' Area is meant to be an One-Pager about all Important Insights, Risks and Opportunities to solely analyze a single corporate.

Company descriptions
UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients;